DailySand tracks obesity drugs across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where obesity drugs appears in today's cross-sector intelligence briefing.
1 item across 1 digest
Eli Lilly is widening its lead over Novo Nordisk in the obesity drug market as Novo struggles to regain market share and investor confidence. The divergence signals a market leadership shift in GLP-1 pharmaceuticals with significant implications for competitive positioning and pipeline risk.
Read original →
DailySand